Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 12,238 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Multiple Diseases Clear all
Not listed Phase 2 Interventional

Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma

NCT00438841
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
bortezomib, cyclophosphamide, dexamethasone, thalidomide
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
10
States / cities
Berkeley, California • Los Angeles, California • Palm Springs, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2009 · Synced Nov 14, 2026, 5:43 PM EST
Completed Phase 3 Interventional Results available

Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy

NCT00232141
View directory record Official record
Conditions
HIV Infections, Peripheral Neuropathy
Interventions
pregabalin, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Nov 14, 2026, 5:43 PM EST
Completed Phase 3 Interventional Results available

Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

NCT02674854
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) ophthalmic solution 0.02%, Latanoprost ophthalmic solution 0.005%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Nov 14, 2026, 5:43 PM EST
Completed Phase 3 Interventional

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

NCT03422822
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Abrocitinib 100 mg, Abrocitinib 200 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
3,166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
156
States / cities
Birmingham, Alabama • Anaheim, California • Encinitas, California + 101 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Nov 14, 2026, 5:43 PM EST
Not listed Phase 2 Interventional

Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver

NCT00408551
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
floxuridine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Goshen Health System
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Goshen, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Nov 14, 2026, 5:43 PM EST
Recruiting No phase listed Observational

Complementary and Alternative Care in Multiple Sclerosis

NCT01703429
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Bastyr University
Other
Eligibility
18 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2030
U.S. locations
1
States / cities
Kenmore, Washington
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Nov 14, 2026, 5:43 PM EST
Completed Not applicable Interventional

Home Testing of Day and Night Closed Loop With Pump Suspend Feature

NCT02523131
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune Diseases
Interventions
FlorenceM, Medtronic insulin pump 640G
Device
Lead sponsor
University of Cambridge
Other
Eligibility
6 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Aurora, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Nov 14, 2026, 5:43 PM EST
Terminated Phase 2 Interventional Results available

A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD)

NCT02901431
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Placebo, RO5285119
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
5 Years to 17 Years
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
45
States / cities
Dothan, Alabama • Phoenix, Arizona • Orange, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Nov 14, 2026, 5:43 PM EST
Completed Phase 2Phase 3 Interventional

Enhanced CBTi for Older Adult Sleep and Cognition

NCT05015803
View directory record Official record
Conditions
Insomnia, Alzheimers Disease Related Dementias
Interventions
CBTi with Application, CBTi, Sleep Hygiene Education
Combination Product · Behavioral
Lead sponsor
Penn State University
Other
Eligibility
60 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Nov 14, 2026, 5:43 PM EST
Completed Phase 1Phase 2 Interventional

Natural Antioxidants in the Treatment of Multiple Sclerosis

NCT00010842
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ginkgo biloba, Alpha-lipoic acid, Vitamin E/Selenium, Essential fatty acids
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
0 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Nov 14, 2026, 5:43 PM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration

NCT07780383
View directory record Official record
Conditions
Alzheimer's Disease, Healthy Participants
Interventions
BMS-986446
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
6
States / cities
Anaheim, California • Bradenton, Florida • Daytona Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 14, 2026, 5:43 PM EST
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity

NCT07476118
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Brenipatide, Placebo
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 14, 2026, 5:43 PM EST
Recruiting No phase listed Observational

Patterns of Neurodevelopmental Disorders

NCT06213090
View directory record Official record
Conditions
Neurodevelopmental Disorders, Autism Spectrum Disorder, Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infection, Pediatric Acute-Onset Neuropsychiatric Syndrome, Down Syndrome, Epilepsy, Mitochondrial Encephalomyopathies, Cerebral Folate Deficiency
Interventions
Not listed
Lead sponsor
Richard Frye
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Nov 14, 2026, 5:43 PM EST
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome

NCT00919113
View directory record Official record
Conditions
Interstitial Cystitis, Painful Bladder Syndrome
Interventions
2% sodium chondroitin sulfate, Placebo
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
20
States / cities
Boulder, Colorado • Denver, Colorado • Farmington, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Nov 14, 2026, 5:43 PM EST
Completed Phase 3 Interventional Results available

A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]

NCT00160524
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab Pegol (CDP870)
Biological
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years and older
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
47
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Nov 14, 2026, 5:43 PM EST
Terminated Phase 3 Interventional Results available

Long-term Extension Study of Ligelizumab in Food Allergy

NCT05678959
View directory record Official record
Conditions
Food Allergy
Interventions
Ligelizumab 120 mg, Ligelizumab 240 mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 57 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
25
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Nov 14, 2026, 5:43 PM EST
Recruiting Not applicable Interventional

Skeletal Muscle Aging and Responsiveness in Aged People With MS

NCT07500727
View directory record Official record
Conditions
Multiple Sclerosis, Aging
Interventions
Exercise trial consisting of both cardiovascular and strength training
Other
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
60 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 12, 2026 · Synced Nov 14, 2026, 5:43 PM EST
Terminated Phase 2 Interventional Results available

Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema

NCT00874497
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
tetomilast, placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
15
States / cities
Birmingham, Alabama • Torrance, California • Kissimmee, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Nov 14, 2026, 5:43 PM EST
Terminated No phase listed Observational Accepts healthy volunteers

Effects of Multiple Concussions in Retired NHL Players

NCT02746523
View directory record Official record
Conditions
Cognitive Deficits, Proprioceptive Disorders
Interventions
Sensory Organization Test, Biomarkers, Conners' Adult ADHD Rating Scale (CAARS), Depression Scale, Cognitive Assessment
Other · Genetic
Lead sponsor
New York Institute of Technology
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Old Westbury, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Nov 14, 2026, 5:43 PM EST
Withdrawn Phase 2 Interventional

Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency Anemia

NCT04968379
View directory record Official record
Conditions
Iron Deficiency, Anaemia
Interventions
Ferric carboxymaltose
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
Up to 1 Year
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Iowa City, Iowa • New Hyde Park, New York • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2023 · Synced Nov 14, 2026, 5:43 PM EST
Completed Phase 4 Interventional

Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension

NCT00300079
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
brinzolamide 1.0%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Nov 14, 2026, 5:43 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients

NCT02568046
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Sym004, FOLFIRI
Drug
Lead sponsor
Symphogen A/S
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Nov 14, 2026, 5:43 PM EST
Active, not recruiting Phase 2 Interventional

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

NCT05014646
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Cholestyramine, Leflunomide
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Duarte, California • Detroit, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Nov 14, 2026, 5:43 PM EST
Recruiting Not applicable Interventional

Central Vein Sign in Multiple Sclerosis Extension Study

NCT07424027
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
MRI Contrast
Diagnostic Test
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Nov 14, 2026, 5:43 PM EST